Brief: Grand Pharmaceutical Says Application Of Phase II Clinical Study Of STC3141 Accepted By NMPA
15/06/2023 11:06
June 15 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE IB CLINICAL TRIAL OF STC3141 FOR TREATMENT OF SEPSIS
IN
AUSTRALIA AND BELGIUM REACHED CLINICAL ENDPOINT
* STC3141 SHOWED FAVORABLE SAFETY AND WAS WELL TOLERATED IN
GENERAL IN PRIMARY ENDPOINT OF THE STUDY
* IN ADDITION, APPLICATION OF PHASE II CLINICAL STUDY OF
STC3141
HAS BEEN OFFICIALLY ACCEPTED BY NMPA
Further company coverage: 0512.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement